Atlas FDA

HER2 CISH PHARMDX KIT

FDA premarket approval P100024 · decided 2011-11-30

Approval details

PMA number
P100024
Trade name
HER2 CISH PHARMDX KIT
Generic name
Chromogenic in situ hybridization, nucleic acid amplification, HER2/NEU gene, breast cancer
Applicant
Dako Denmark A/S
Date received
2010-06-21
Decision date
2011-11-30
Days to decision
527 days
Decision code
APWD
Product code
NYQ
Advisory committee
Pathology
Expedited review
No
Location
Glostrup
Statement
APPROVAL FOR THE HER2 CISH PHARMDX KIT. THIS DEVICE IS INDICATED TOR;HER2 CISH PHARMDX KIT IS INTENDED FOR DUAL-COLOR CHROMOGENIC VISUALIZATION OF SIGNALS ACHIEVED WITH DIRECTLY LABELED IN SITU HYBRIDIZATION PROBES TARGETING THE HER2 GENE AND CENTROMERIC REGION OF CHROMOSOME 17. THE KIT IS DESIGNED TO QUANTITATIVELY DETERMINE HER2 GENE STATUS IN FORMALIN-FIXED, PARAFFIN-EMBEDDED BREAST CANCER TISSUE SPECIMENS. RED AND BLUE CHROMOGENIC SIGNALS ARE GENERATED ON THE SAME TISSUE SECTION FOR EVALUATI

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EPI, RTU (Dako Onmis) (K170028)Dako Denmark A/S2017-12-21
FLEX Monoclonal Mouse Anti-Human Progesterone Receptor, Clone PgR 1294, Ready-to-Use (Dako Omnis) (K170005)Dako Denmark A/S2017-12-21